Provided by Tiger Trade Technology Pte. Ltd.

Solid Biosciences

9.58
-0.1900-1.94%
Post-market: 9.770.1900+1.98%19:30 EDT
Volume:686.62K
Turnover:6.54M
Market Cap:1.03B
PE:-5.12
High:9.73
Open:9.73
Low:9.37
Close:9.77
52wk High:11.45
52wk Low:3.79
Shares:107.23M
Float Shares:64.81M
Volume Ratio:0.75
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8709
EPS(LYR):-1.9922
ROE:-65.50%
ROA:-36.38%
PB:2.75
PE(LYR):-4.81

Loading ...

Solid Biosciences price target raised to $26 from $16 at Cantor Fitzgerald

TIPRANKS
·
Aug 27

Solid Biosciences Price Target Raised to $26.00/Share from $16.00 by Cantor Fitzgerald

Dow Jones
·
Aug 27

Solid Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Solid Biosciences: Advancing Gene Therapy Pipeline, Strong Cash Runway Support Buy Rating with Unchanged $14 Price Target

TIPRANKS
·
Aug 10

Solid Biosciences Inc Expected to Post a Loss of 48 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Wedbush Adjusts PT on Solid Biosciences to $15 From $16, Maintains Outperform Rating

MT Newswires Live
·
Aug 07

Solid Biosciences Q2 EPS $(0.38) Beats $(0.46) Estimate

Benzinga Earnings
·
Aug 07

Solid Biosciences Updates Shelf for $200 Million Offering

TIPRANKS
·
Aug 07

Solid Biosciences Files Prospectus for up to $200 Million At-the-Market Stock Offering

Reuters
·
Aug 07

Solid Biosciences reports Q2 EPS (38c), consensus (47c)

TIPRANKS
·
Aug 07

Solid Biosciences Inc Files for Offering of up to $200 Mln in Common Stock - SEC Filing

THOMSON REUTERS
·
Aug 07

Solid Biosciences Inc Files for Mixed Shelf; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Aug 07

Solid Biosciences Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 07

Solid Biosciences Q2 FY26 Net Loss Widens 38.8% to $54.8 Million

Reuters
·
Aug 07

Press Release: Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Dow Jones
·
Aug 07

Is Solid Biosciences (SLDB) Undervalued Following Its Russell Growth Index Additions?

Simply Wall St.
·
Jul 08

Analysts Conflicted on These Healthcare Names: Nuvalent (NUVL) and Solid Biosciences (SLDB)

TIPRANKS
·
Jul 06

Solid Biosciences Initial Beneficial Ownership Filing Shows RA Capital Management Stake

Reuters
·
Jun 25

Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?

Simply Wall St.
·
Jun 19

Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says

MT Newswires Live
·
Jun 18